Rajesh Pahwa
#157,995
Most Influential Person Now
Rajesh Pahwa's AcademicInfluence.com Rankings
Rajesh Pahwaphilosophy Degrees
Philosophy
#8995
World Rank
#12485
Historical Rank
Logic
#6002
World Rank
#7472
Historical Rank
Rajesh Pahwabiology Degrees
Biology
#12289
World Rank
#15755
Historical Rank
Neuroscience
#2048
World Rank
#2105
Historical Rank
Download Badge
Philosophy Biology
Rajesh Pahwa's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Neuroscience University of California, San Francisco
Why Is Rajesh Pahwa Influential?
(Suggest an Edit or Addition)Rajesh Pahwa's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. (2010) (1131)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000) (921)
- Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes (2006) (916)
- Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. (2011) (814)
- Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. (2009) (724)
- Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. (2004) (609)
- A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. (2002) (547)
- Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. (2003) (538)
- Neuropathological changes in essential tremor: 33 cases compared with 21 controls. (2007) (500)
- Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology (2006) (496)
- High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor (1997) (493)
- Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease (2009) (390)
- Basic algorithms for the programming of deep brain stimulation in Parkinson's disease (2006) (352)
- Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial (2012) (335)
- Age at onset in two common neurodegenerative diseases is genetically controlled. (2002) (332)
- Long-term evaluation of deep brain stimulation of the thalamus. (2006) (329)
- Complete genomic screen in Parkinson disease: evidence for multiple genes. (2001) (302)
- A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. (2014) (294)
- Long‐term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor (2001) (288)
- Surgical and hardware complications of subthalamic stimulation (2004) (287)
- Deep brain stimulation: Preoperative issues (2006) (278)
- Randomized trial of deep brain stimulation for Parkinson disease (2012) (261)
- Advanced Parkinson disease treated with rotigotine transdermal system (2007) (258)
- High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease (1997) (245)
- Handbook of Parkinson's Disease (1987) (245)
- Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. (2003) (224)
- A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease (2006) (224)
- Ropinirole 24-hour prolonged release (2007) (218)
- Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease (2003) (212)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Reduced Purkinje cell number in essential tremor: a postmortem study. (2008) (197)
- Criteria for the diagnosis of essential tremor. (2000) (196)
- Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. (2001) (190)
- Neuropsychological deficits in essential tremor: an expression of cerebello‐thalamo‐cortical pathophysiology? (2002) (167)
- Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor (2001) (164)
- Unilateral pallidal stimulation for Parkinson's disease: Neurobehavioral functioning before and 3 months after electrode implantation (1997) (164)
- Understanding verbal fluency in healthy aging, Alzheimer's disease, and Parkinson's disease. (2011) (163)
- MECHANISM OF ACTION (2019) (147)
- Quality of life in Essential Tremor Questionnaire (QUEST): development and initial validation. (2005) (146)
- Clinical expression of essential tremor: Effects of gender and age (1997) (146)
- Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. (2003) (143)
- Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial (2017) (143)
- Neuropathologic findings in essential tremor (2006) (143)
- Apolipoprotein E controls the risk and age at onset of Parkinson disease (2004) (140)
- National randomized controlled trial of virtual house calls for Parkinson disease (2017) (140)
- Reliability of a new scale for essential tremor (2012) (136)
- Bilateral thalamic stimulation for the treatment of essential tremor. (1999) (136)
- Interactive video conferencing: A means of providing interim care to parkinson's disease patients (1993) (134)
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial (2017) (132)
- Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study) (2015) (131)
- Neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (1999) (130)
- Topiramate in essential tremor (2006) (129)
- Efficacy of unilateral deep brain stimulation of the vim nucleus of the thalamus for essential head tremor (1999) (124)
- Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3) (2017) (123)
- Double‐blind controlled trial of gabapentin in essential tremor (1998) (121)
- Deep brain stimulation and tremor (2008) (108)
- Botulinum toxin treatment of essential head tremor (1995) (102)
- Deep Brain Stimulation and Essential Tremor (2004) (102)
- Neuropsychological and quality of life outcomes 12 months after unilateral thalamic stimulation for essential tremor (2003) (101)
- Therapy of Parkinson's disease (1990) (100)
- Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience (1998) (100)
- Benefits and Risks of Pharmacological Treatments for Essential Tremor (2003) (99)
- Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines. (2010) (98)
- Essential tremor: differential diagnosis and current therapy. (2003) (97)
- Gender differences in Parkinson's disease. (1998) (93)
- Development and initial validation of a screening tool for Parkinson disease surgical candidates (2004) (92)
- Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor (2001) (91)
- Effects of bilateral subthalamic nucleus stimulation on sleep, daytime sleepiness, and early morning dystonia in patients with Parkinson disease. (2006) (91)
- Long-term benefits in quality of life provided by bilateral subthalamic stimulation in patients with Parkinson disease. (2005) (90)
- Olfactory function in essential tremor (1992) (90)
- Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families (2007) (90)
- Reduction in voice tremor under thalamic stimulation (1998) (87)
- Motor Complications of Chronic Levodopa Therapy in Parkinson's Disease (1997) (85)
- Interactions between deep brain stimulation and levodopa in Parkinson’s disease (2001) (83)
- Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease (2010) (83)
- Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. (2014) (82)
- Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease (1996) (81)
- Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. (2011) (80)
- Mitochondrial respiration and respiration‐associated proteins in cell lines created through Parkinson’s subject mitochondrial transfer (2010) (79)
- Preoperative Clinical Predictors of Response to Bilateral Subthalamic Stimulation in Patients with Parkinson’s Disease (2005) (77)
- Effects of thalamic deep brain stimulation based on tremor type and diagnosis (1997) (77)
- Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains (2009) (76)
- Deep brain stimulation for essential tremor. (2013) (74)
- The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson's disease. (2011) (71)
- Health-Related Quality of Life in Parkinson's Disease after Pallidotomy and Deep Brain Stimulation (2000) (70)
- Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. (2011) (69)
- MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy (2011) (67)
- Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose (2007) (67)
- Handbook of Essential Tremor and Other Tremor Disorders (2005) (66)
- Freezing of gait after bilateral subthalamic nucleus stimulation for Parkinson's disease (2006) (66)
- Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability. (2011) (66)
- Cognitive outcome following staged bilateral pallidal stimulation for the treatment of Parkinson’s disease (1999) (65)
- Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study (2020) (65)
- Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial (2019) (64)
- Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study (2014) (64)
- Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. (2003) (62)
- Effect of stimulation frequency on tremor suppression in essential tremor (2004) (62)
- Clinical experience with controlled‐release carbidopa/levodopa in Parkinson's disease (1993) (60)
- Effect of Motor Improvement on Quality of Life following Subthalamic Stimulation Is Mediated by Changes in Depressive Symptomatology (2004) (60)
- Neuropsychological and Quality of Life Changes Following Unilateral Thalamic Deep Brain Stimulation in Parkinson's Disease: A One-Year Follow-up (2001) (60)
- Older onset essential tremor: More rapid progression and more degenerative pathology (2009) (59)
- Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N‐0923 TDS: A double‐blind, placebo‐controlled study (2001) (59)
- Is there a relationship between Parkinson's disease and essential tremor? (1993) (59)
- The impact and management of nonmotor symptoms of Parkinson's disease. (2011) (57)
- Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor. (2012) (57)
- Levodopa-related wearing-off in Parkinson's disease: identification and management (2009) (57)
- Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study (2019) (55)
- Pharmacotherapy of Essential Tremor (2008) (55)
- Improvements in daily functioning after deep brain stimulation of the thalamus for intractable tremor (1998) (55)
- A comparison of Parkinson's disease symptoms and self-reported functioning and well being. (1997) (54)
- A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease (2001) (54)
- Levetiracetam is Not Effective for Essential Tremor (2007) (53)
- Surgical treatment of Parkinson’s disease (1999) (52)
- Thalamic DBS with a constant-current device in essential tremor: A controlled clinical trial. (2017) (52)
- Open-label trial regarding the use of acupuncture and yin tui na in Parkinson's disease outpatients: a pilot study on efficacy, tolerability, and quality of life. (2006) (51)
- Treatment of Early Parkinson’s Disease (2009) (50)
- Subthalamic nucleus deep brain stimulation changes speech respiratory and laryngeal control in Parkinson’s disease (2010) (50)
- Pharmacokinetic‐pharmacodynamic crossover comparison of two levodopa extension strategies (2009) (50)
- Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. (2015) (48)
- Effect and Time Course of Deep Brain Stimulation of the Globus Pallidus and Subthalamus on Motor Features of Parkinson's Disease (2000) (48)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. (2016) (47)
- Glucocerebrosidase mutations in diffuse Lewy body disease. (2011) (46)
- Surgical treatment of essential tremor. (2000) (45)
- Pioglitazone in early Parkinson's disease (2015) (45)
- Analysis of pallidotomy lesion positions using three-dimensional reconstruction of pallidal lesions, the basal ganglia, and the optic tract. (1997) (45)
- Efficacy and Tolerability of Levetiracetam in Parkinson Disease Patients With Levodopa-Induced Dyskinesia (2006) (45)
- Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED] (2006) (44)
- Postural Sway in Patients with Mild to Moderate Parkinson's Disease (2011) (44)
- Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects (2010) (41)
- An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor (2019) (41)
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study (2017) (40)
- Early biomechanical markers of postural instability in Parkinson's disease. (2009) (40)
- Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson’s disease: recommendations from an expert panel (2018) (40)
- Brain activity during dual task gait and balance in aging and age-related neurodegenerative conditions: A systematic review (2019) (39)
- Treating motor fluctuations with controlled-release levodopa preparations. (1994) (38)
- Pulse width is associated with cognitive decline after thalamic stimulation for essential tremor. (2003) (38)
- A review of ropinirole prolonged release in Parkinson’s disease (2009) (38)
- Qigong exercise may improve sleep quality and gait performance in Parkinson's disease: a pilot study (2015) (37)
- Comparison of the Fahn‐Tolosa‐Marin Clinical Rating Scale and the Essential Tremor Rating Assessment Scale (2018) (37)
- Classification of Parkinson’s disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach (2020) (37)
- Long-Term Efficacy of Globus pallidus Stimulation for the Treatment of Parkinson’s Disease (2003) (37)
- A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. (2008) (36)
- Treatment patterns and associated costs with Parkinson's disease levodopa induced dyskinesia (2012) (36)
- Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia (2018) (35)
- Effect of deep brain stimulation of the subthalamic nucleus upon the contralateral subthalamic nucleus in Parkinson disease (2009) (34)
- Double‐blind controlled study of methazolamide in the treatment of essential tremor (1993) (34)
- Thalamic stimulation for midbrain tremor after partial hemangioma resection (2002) (34)
- A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. (2013) (32)
- Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of ‘off’ episodes in patients with Parkinson's disease (2007) (32)
- Predictors of Mild Cognitive Impairment in Early-Stage Parkinson's Disease (2013) (31)
- Diabetes mellitus presenting as paroxysmal kinesigenic dystonic choreoathetosis (1995) (31)
- Head positioning and risk of pneumocephalus, air embolism, and hemorrhage during subthalamic deep brain stimulation surgery (2010) (31)
- Feasibility of group voice therapy for individuals with Parkinson's disease. (2011) (30)
- Mirtazapine in essential tremor: A double‐blind, placebo‐controlled pilot study (2003) (29)
- Pramipexole in Levodopa-treated Parkinson Disease Patients of African, Asian, and Hispanic Heritage (2007) (29)
- Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. (2001) (29)
- Dyskinesia Matters (2019) (28)
- Levodopa-related wearing-off in Parkinson's disease: identification and management. (2009) (28)
- Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. (2019) (28)
- Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease (2017) (27)
- Comparison of standard carbidopa–levodopa and sustained‐release carbidopa–levodopa in parkinson's disease: Pharmacokinetic and quality‐of‐life measures (1997) (27)
- Paradoxical Effect of Dopamine Medication on Cognition in Parkinson’s Disease: Relationship to Side of Motor Onset (2015) (26)
- Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. (2019) (26)
- Postural tremor suppression is dependent on thalamic stimulation frequency (2006) (25)
- Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. (2020) (25)
- Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062) (2013) (25)
- Common and unique responses to dopamine agonist therapy and deep brain stimulation in Parkinson’s disease: An H2 15O PET study (2012) (24)
- Neuropsychological functioning before and after unilateral thalamic stimulating electrode implantation in Parkinson's disease (1997) (24)
- Subthalamic nucleus deep brain stimulation changes velopharyngeal control in Parkinson's disease. (2011) (24)
- Effective Management Approaches for Psychosis in Patients With Parkinson Disease (2018) (23)
- Prediction of the Levodopa Challenge Test in Parkinson’s Disease Using Data from a Wrist-Worn Sensor (2019) (23)
- Utility of the NeuroTrax Computerized Battery for Cognitive Screening in Parkinson's Disease: Comparison with the MMSE and the MoCA (2010) (23)
- Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor (2020) (23)
- The effect of acetazolamide on essential tremor (1992) (23)
- Use of Brain MRI after Deep Brain Stimulation Hardware Implantation (2010) (22)
- Ropinirole therapy for Parkinson’s disease (2004) (22)
- Electronic motor function diary for patients with Parkinson's disease: a feasibility study. (2007) (22)
- Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease (2018) (22)
- The effect of moderate Parkinson's disease on compensatory backwards stepping. (2013) (22)
- The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review (2021) (22)
- Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective (2017) (21)
- Conversion From Sustained Release Carbidopa/Levodopa to Carbidopa/Levodopa/Entacapone (Stalevo) in Parkinson Disease Patients (2006) (21)
- Presurgical Coping, Depression, and Quality of Life in Persons with Parkinson's Disease (2003) (21)
- Current Practices for Outpatient Initiation of Levodopa-Carbidopa Intestinal Gel for Management of Advanced Parkinson’s Disease in the United States (2019) (20)
- Deep brain stimulation in Parkinson’s disease (2004) (20)
- Early morning akinesia in Parkinson's disease (1996) (20)
- Cognitive impairment in Parkinson's disease (1998) (19)
- Surgical treatment options in Parkinson's disease. (1998) (19)
- Understanding Parkinson's disease: an update on current diagnostic and treatment strategies. (2006) (18)
- Symptomatic, non-infectious, non-hemorrhagic edema after subthalamic nucleus deep brain stimulation surgery for Parkinson's disease (2017) (18)
- Validity of clinical and patient ratings of tremor disability among older adults. (2003) (17)
- Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson’s disease (2003) (17)
- Treatment of early Parkinson's disease. (2014) (17)
- Bilateral Pallidotomy for Severe Dystonia in an 18-Month-Old Child with Glutaric Aciduria (2004) (17)
- Comparison of Actual Pallidotomy Lesion Location with Expected Stereotactic Location (1999) (17)
- The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients. (2018) (16)
- Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose study (1996) (16)
- Diagnosis and Initiation of Treatment in Parkinson's Disease (2011) (16)
- EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease (2020) (15)
- Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review. (2011) (15)
- Essential tremor with ubiquitinated Purkinje cell intranuclear inclusions (2010) (15)
- Reduced Purkinje Cell Number in Essential Tremor (2008) (15)
- Old Drugs, New Delivery Systems in Parkinson’s Disease (2019) (14)
- Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102 (2018) (14)
- Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease (2021) (14)
- Deep brain stimulation of the subthalamic nucleus in Parkinson's disease patients over 75 years of age (2019) (13)
- Subthalamic Nucleus Stimulation in Parkinson’s Disease Patients Intolerant to Levodopa (2007) (13)
- ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. (2017) (13)
- Objective measurement in Parkinson’s disease: a descriptive analysis of Parkinson’s symptom scores from a large population of patients across the world using the Personal KinetiGraph® (2020) (13)
- Lesion Volume and Clinical Outcome in Stereotactic Pallidotomy and Thalamotomy (1999) (13)
- Parkinson's Disease: Questions and Answers (1997) (12)
- Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus (2018) (12)
- Complete genomic screen in Parkinson Disease (2001) (12)
- MDS-UPDRS to assess non-motor symptoms after STN DBS for Parkinson's disease (2016) (12)
- Stimulation of the motor cortex for disabling essential tremor (2006) (12)
- Pupillary Response to Cognitive Demand in Parkinson’s Disease: A Pilot Study (2018) (11)
- Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review. (2004) (11)
- Advances in the treatment of Parkinson's disease. (1998) (11)
- The UPDRS-8: A Brief Clinical Assessment Scale for Parkinson's Disease (2012) (10)
- Dopamine agonists in the treatment of Parkinson's disease. (1995) (9)
- Green Tea Consumption Reduces Oxidative Stress in Parkinson’s Disease Patients (2015) (9)
- Identical twins with similar onset of Parkinson's disease (1993) (9)
- Long Term Response to Levodopa in Parkinson's Disease. (2019) (9)
- Erratum: Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease (Human Molecular Genetics (2003) vol. 12 (3259-3267)) (2004) (8)
- Behavioral Relaxation Training for Parkinson's Disease Related Dyskinesia and Comorbid Social Anxiety. (2013) (8)
- Prevalence of bone mineral density screening in Parkinson's disease clinic outpatients (2006) (8)
- Erratum: Long-term benefits in quality of life after unilateral thalamic deep brain stimulation for essential tremor : Clinical article (2012) (8)
- Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia (2021) (8)
- A Phase 2 Proof‐of‐Concept, Randomized, Placebo‐Controlled Trial of CX‐8998 in Essential Tremor (2021) (8)
- An open‐label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease (2009) (8)
- P2.152 Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials (2009) (7)
- Extended-Release Amantadine for Levodopa-Induced Dyskinesia (2019) (7)
- Controlled‐release levodopa (1993) (7)
- Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. (2019) (7)
- Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (2018) (7)
- Progressive supranuclear palsy. (1999) (7)
- Reliability and Validity of Pupillary Response during Dual-task Balance in Parkinson's Disease. (2020) (7)
- Magnetic resonance image evaluation of pallidotomy lesions: a volumetric and shape analysis. (1997) (7)
- Outpatient titration of carbidopa/levodopa enteral suspension (Duopa) (2017) (7)
- Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA. (1996) (6)
- The importance of testing deep brain stimulation lead impedances before final lead implantation (2011) (6)
- Management of Essential Tremor (2009) (6)
- Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin (2019) (6)
- Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease. (2013) (5)
- Classification of Parkinson's disease and essential tremor based on gait and balance characteristics from wearable motion sensors: A data-driven approach (2020) (5)
- Deep brain stimulation for Parkinson's disease: current status and future outlook. (2016) (5)
- Statement of Retraction: “Mohamad Goldust, Mahnaz Talebi, Jafar Majidi, Mohammad Amin Rezazadeh Saatlou, and Elham Rezaee. Evaluation of antiphospholipid antibodies in youths suffering from cerebral ischemia.” (2013) (5)
- Effect of Behavioral Intervention on Comorbid General Anxiety Disorder and Parkinson's Disease (2008) (5)
- Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD Psychosis: Analysis of an integrated Phase 3 placebo-controlled dataset (2016) (5)
- Does post-operative symptomatic lead edema associated with subthalamic DBS implantation impact long-term clinical outcomes? (2019) (5)
- Treatment of Early Parkinson’s Disease (2009) (5)
- Comparative Magnetic Resonance Image-Based Evaluation of Thalamotomy and Pallidotomy Lesion Volumes (1999) (4)
- THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial (2021) (4)
- Pupillary Response to Postural Demand in Parkinson’s Disease (2021) (3)
- ADS-5102 provided reduction in motor complications in Parkinson’s disease patients with levodopa-induced dyskinesia switched from amantadine IR: Subgroup analysis from open-label study (ease LID 2) (2017) (3)
- Surgical Treatment of Parkinson's Disease: Past, Present, and Future (2002) (3)
- Dopa-Responsive Parkinsonism Secondary to Right Temporal Lobe Haemorrhage (2002) (3)
- Safety and Efficacy Study of ADS-5102 (Amantadine HCl) Extended Release Capsules in Levodopa-Induced Dyskinesia (EASED Study) (P4.053) (2014) (3)
- Inter-Rater Reliability of the Essential Tremor Rating Assessment Scale (TETRAS) (S32.004) (2012) (3)
- Thalamic Deep Brain Stimulation for Parkinson's Disease Tremor (2008) (3)
- Randomized trial of deep brain stimulation for Parkinson's disease: 36 month outcomes (copy of NEUROLOGY/2011/402453, combining disclosures to single author only) (2012) (3)
- Amantadine: an old drug reborn (2021) (3)
- SETTLE study design: A 24-week, double-blind, placebo-controlled study of the efficacy and safety of safinamide as add-on therapy to levodopa in patients with Parkinson's diseases Add-On Therapy to Levodopa in Patients with Parkinson's disease (2010) (3)
- A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052) (2018) (3)
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose-titration phase (2018) (2)
- Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease. (2020) (2)
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF-episodes in subjects with Parkinson’s disease: preliminary results from the Phase-3 study dose titration phase (2018) (2)
- Cognitive workload during verbal abstract reasoning in Parkinson’s disease: a pilot study (2020) (2)
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: results from the Phase 3 study dose-titration phase (P1.017) (2017) (2)
- P2.174 Long-term safety of rotigotine transdermal patch in early-stage Parkinson's disease: four year results (2009) (2)
- Impact of Off time on Quality of Life and Caregiver Burden in Parkinson’s Disease (P6.007) (2017) (2)
- Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson’s Disease: Real-World Evidence From G7 Countries (2022) (2)
- Thalamic Deep Brain Stimulation and Essential Tremor (2008) (2)
- Thirty Second Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders (2019) (2)
- Current issues in the diagnosis and treatment of Parkinson's disease. Introduction. (2011) (2)
- Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis (2022) (2)
- Effects of Balance Training on Nonmotor Symptoms in Individuals With Parkinson Disease (2020) (1)
- Long-term safety and efficacy of MYOBLOC® (rimabotulinumtoxinB) in the treatment of adult sialorrhea (2018) (1)
- Development, Efficacy and Safety of Once-daily, Bedtime, Extended-release Amantadine (Gocovri®) to Treat Dyskinesia and OFF Time in Parkinson’s Disease (2021) (1)
- Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's disease: Results from a pooled meta-analysis. (2019) (1)
- Effects of ADS-5102 on non-motor symptoms (NMS) in Parkinson’s disease patients with dyskinesia (P1.039) (2018) (1)
- Objective Data in Parkinson’s Disease: A description of over 10,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) (P3.039) (2018) (1)
- Evaluation of morning bradykinesia in Parkinson’s disease in a United States cohort using continuous objective monitoring (2022) (1)
- 2.238 Ropinirole 24-hour prolonged-release adjunctive therapy improves cardinal symptoms in patients with advanced Parkinson's disease not optimally controlled with L-dopa (2007) (1)
- Efficacy Result from a Phase 2, Double-Blind, Placebo-Controlled Study of CX-8998 a State-Dependent T-Type Calcium (Cav3) Channel Modulator in Essential Tremor Patients (T-CALM) (S4.008) (2019) (1)
- Pharmacology and Evidence-Based Strategies for Current and Emerging Treatments for OFF Periods in Parkinson Disease. (2020) (1)
- Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease. (2014) (1)
- A New Perspective in the Treatment of Parkinson’s Disease Psychosis (2016) (1)
- Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up (2022) (1)
- Diagnosis and prognosis of new-onset Parkinson's disease (2006) (1)
- Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. (2022) (1)
- Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea (2020) (1)
- Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea (2020) (1)
- Pharmacologic management of Parkinson disease : Initial therapy (2006) (1)
- CLINICAL DIAGNOSTIC ACCURACY IN THE UNIVERSITY OF KANSAS ALZHEIMERʼS DISEASE CENTER: 77 (1995) (1)
- Safety and Efficacy of Continuous Apomorphine Infusion in Patients with Parkinson's disease: Results from a Phase 3, Open-label Study (2020) (1)
- Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease (2008) (1)
- Maintenance of Tremor Control Over Time in Patients with Essential Tremor Using Chronic Thalamic Stimulation: 780 (1997) (1)
- Animal Models of Essential Tremor (2005) (1)
- Rotigotine skin patch for the treatment of fluctuating Parkinson's disease—how does it compare with pramipexole? (2007) (1)
- Parkinson's disease and parkinsonism in the elderly: Essential tremor in the elderly (2000) (1)
- Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel (2022) (1)
- Objective Evaluation of Levodopa Response on Gait and Balance (P2.041) (2018) (1)
- Parkinson’s Disease: An Overview of Etiology, Clinical Manifestations, and Treatment (2014) (1)
- Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? (2022) (1)
- Current treatment challenges and emerging therapies in Parkinson's disease (2004) (1)
- Deep brain stimulation. Authors' reply (2005) (1)
- Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus (2019) (1)
- Exploring essential tremor: Results from a large online survey (2016) (1)
- Subject Index Vol. 79, 2002 (2003) (0)
- Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis (P4.7-010) (2019) (0)
- Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini (2020) (0)
- 772 Complications of Stereotactic Surgery for Movement Disorders (2001) (0)
- Management of Stimulation-Induced Dyskinesia in Parkinson Disease With Interleaving Programming Settings (2020) (0)
- Papers to Appear in Forthcoming Issues (1999) (0)
- American Society for Stereotactic and Functional Neurosurgery Bestows Distinguished Service Award on Dr. med. h.c. mult. Thomas Karger and Prof. Dr. Phil Gildenberg (2004) (0)
- 23 Deep Brain Stimulation in Parkinson ’ s Disease (2005) (0)
- Introduction (2011) (0)
- Managing essential tremor patients treated with deep brain stimulation (2015) (0)
- Handbook of Parkinson's Disease, Fourth Edition (2003) (0)
- Corrigendum: Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: An expert consensus (CNS Spectrums (2018) 23:6 (402-413) DOI: 10.1017/S1092852918001359) (2019) (0)
- Three-Year Follow-Up of a Prospective, Double Blinded Multi-Center RCT Evaluating DBS with a Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson's Disease (INTREPID) (2020) (0)
- Pooled analysis of phase 3 studies of ADS-5102 for levodopa-induced dyskinesia: A detailed review of MDS-UPDRS, part IV (motor complications) (2018) (0)
- Progress in Neurotherapeutics and Neuropsychopharmacology: Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD-Adjunct Study) (2008) (0)
- Editorial Advisory Board Co-Editors-in-Chief: (2012) (0)
- Classification of Parkinson’s disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach (2020) (0)
- How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature (2022) (0)
- The characterization of a base-width neutral step as the first step for balance recovery in moderate Parkinson's disease (2016) (0)
- Tremor: Phenomenology, Etiology, Diagnosis, and Treatment (2017) (0)
- Creating the Picks disease International Consortium: Association study of MAPT H2 haplotype with risk of Picks disease (2023) (0)
- Movement Disorder Specialists Survey Regarding Use of Telemedicine During the COVID-19 Pandemic. (2022) (0)
- Beneficial Effects of Green Tea Consumption in Parkinson's Disease Patients (2013) (0)
- Subject Index Vol. 71, 1998 (1999) (0)
- Balance training in individuals with Parkinson's disease: Biodex Stability System versus supervised exercise program (2022) (0)
- PAST 3 Surgical Treatment of Parkinson ' s Disease Past , Present , and Future (0)
- Fatigue in Parkinson’s Disease (P5.003) (2017) (0)
- The Eyes as a Window to Understanding Abstract Reasoning in Parkinson's Disease (2018) (0)
- 2.241 Relationship between awake time spent “off” and systemic exposure of ropinirole 24-hour prolonged release in patients with advanced Parkinson's disease (2007) (0)
- Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases (S51.004) (2023) (0)
- An Open-Label Pilot Study of Transdermal Selegiline for Depression in Parkinson’s Disease Patients (2008) (0)
- 2.205 Design of the A to Z (Agonists to Zelapar) trial: Adding orally disintegrating selegiline to dopamine agonists in patients with Parkinson's disease experiencing complications (2007) (0)
- Task Evoked Pupillary Response Reflects Task Complexity in Parkinson’s Disease: A Pilot Study (2017) (0)
- National Parkinson Foundation Hospitalization Survey (2014) (0)
- Ongoing clinical trials for Parkinson's disease (2006) (0)
- Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses (2022) (0)
- Characterizing a Parkinson’s Disease Population Inadequately Controlled by Oral Therapy: Baseline Characteristics of the Phase 3 Clinical Program for Foslevodopa/Foscarbidopa (P2-11.006) (2023) (0)
- Comprar Treatment Decisions in Parkinson's Disease | Rajesh Pahwa | 9780195395624 | Oxford University Press (2010) (0)
- Dopaminergic Basis of Spatial Deficits in Early Parkinson's Disease. (2021) (0)
- Comprar Parkinson's Disease | Tanya Simuni | 9780195371727 | Oxford University Press (2010) (0)
- Book Reviews (2008) (0)
- Twelfth annual symposia on etiology, pathogenesis, and treatment of parkinson's disease and etiology, pathogenesis, and treatment of Huntington's disease (1998) (0)
- Medical and surgical treatments for Parkinson's disease (2006) (0)
- Using Objective Measurement Via Wearable Sensors To Evaluate Real-world Effectiveness Of Carbidopa/Levodopa Enteral Suspension For Managing Motor Fluctuations: PROviDE Study Design And Baseline Characteristics (P3.037) (2018) (0)
- Deep Brain Stimulation In Parkinson’s Disease (2003) (0)
- Pallidal Stimulation for Advanced Parkinson's Disease: 775 (1997) (0)
- Contents Vol. 71, 1998 (1999) (0)
- A Comprehensive Virtual Reality Balance Assessment for Parkinson's Disease (2020) (0)
- Thalamotomy vs. DBS of the Thalamus (2002) (0)
- O.077 Treatment of non-motor symptoms of PD (2009) (0)
- Other Tremor Disorders (2005) (0)
- 104 Management of Essential (2009) (0)
- Impact of current antipsychotic medications on comparative mortality and adverse events in people with Parkinson’s disease psychosis (PDP) (2016) (0)
- Magnitude of Microelectrode Refinement in Pallidotomy and Thalamotomy1 (2002) (0)
- Ropinirole 24-h Prolonged Release in Advanced Parkinson Disease: Review of a Randomized, Double-Blind, Placebo-Controlled Study (EASE PD - Adjunct Study) (2008) (0)
- Deep brain stimulation for tremor (2014) (0)
- Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia (2022) (0)
- Quality of life in Essential Tremor Questionnaire (2018) (0)
- A stimulating treatment for essential tremor (2008) (0)
- Effect of Disease Duration on Motor Outcomes After Bilateral Subthalamic Stimulation in Parkinson’s Disease (P3.361) (2016) (0)
- A Survey of Coenzyme Q10 Use in Parkinson's Disease Clinic Outpatients (2005) (0)
- Parkinson’s disease psychosis: A roundtable discussion (2015) (0)
- Effects on Motor and Nonmotor Symptoms of Parkinson's Disease (2013) (0)
- Disease severity does not predict effective ON-turning dose of apomorphine sublingual film (APL-130277) in patient with Parkinson’s disease (P1.023) (2017) (0)
- Reliability of the Essential Tremor Rating Assessment Scale in Untrained Neurology Residents (S53.006) (2013) (0)
- Statement of Retraction: “Kishali NF, Imamoglu O, Kaldirimci M, Akyol P, Yildirim K. Comparison of lipid and lipoprotein values in men and women differing in training status.” (2013) (0)
- Efficacy and Safety of Unilateral MRgFUS Thalamotomy for Tremor-Predominant Parkinson’s Disease (P4-11.002) (2023) (0)
- Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial (2022) (0)
- Study design and rationale for an international study of DBS for movement disorders (2020) (0)
- Clinical Experience with Outpatient Initiation of Carbidopa/Levodopa Enteral Suspension in Parkinson’s Disease Patients in the Medication ON State (P1.029) (2017) (0)
- Papers to Appear in Forthcoming Issues (1999) (0)
- Pooled Analysis of Phase 3 studies of ADS-5102 (amantadine hydrochloride) extended release capsules for Levodopa-Induced Dyskinesia: A detailed review of UDysRS Results (S56.003) (2017) (0)
- Appendix D: Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidenced-based review): Report of the Quality Standards Subcommitte of the American Academy of Neurology (2007) (0)
- Khodakarami, H., et al., Prediction of the Levodopa Challenge Test in Parkinson’s Disease Using Data from a Wrist-Worn Sensor. Sensors 2019, 19, 5153 (2020) (0)
- Subject Index Vol. 80, 2003 (2004) (0)
- Effects of Subthalamic Stimulation in Elderly patients with Parkinson Disease (S39.006) (2017) (0)
- Contents Vol. 79, 2002 (2003) (0)
- Detecting bradykinesia in early morning “OFF” episodes: a large database study using the Personal KinetiGraph® (PKG®) (2020) (0)
- Case-based Medical Education Improves Neurologists’ Competence in Diagnosing and Managing Levodopa-induced Dyskinesia (P5.8-036) (2019) (0)
- Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios (2022) (0)
- Treatments for progressing Parkinson's disease: a clinical case scenario study. (2009) (0)
- Efficacy and Safety of Unilateral MRgFUS Thalamotomy for Essential Tremor (P7-11.006) (2023) (0)
- A diffusion-tensor imaging study of white matter microstructure in neurodegenerative disease (2013) (0)
- Continuous, Subcutaneous Apomorphine Infusion for Persistent Motor Fluctuations in Parkinson’s Disease: Full results of the AP2-3000 open-label study (S32.008) (2023) (0)
- Machine Learning Classification of Parkinson's Disease and Essential Tremor Using Wearable Sensors (2020) (0)
- Unilateral Versus Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation for Axial Essential Tremor Symptoms (S18.003) (2018) (0)
- Deep Brain Stimulation Management: Managing essential tremor patients treated with deep brain stimulation (2010) (0)
- Characterization of Tau Association with Parkinson's Disease (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rajesh Pahwa?
Rajesh Pahwa is affiliated with the following schools:
